What is the recommended medical management of atrial fibrillation in a patient with rheumatic heart disease?

Medical Management of Atrial Fibrillation in Rheumatic Heart Disease

Anticoagulation is Mandatory and Non-Negotiable

All patients with rheumatic heart disease (RHD) and atrial fibrillation require lifelong oral anticoagulation regardless of CHA₂DS₂-VASc score, because rheumatic mitral stenosis is classified as a high-risk factor for stroke. 1

Anticoagulant Selection

• Warfarin remains the anticoagulant of choice for rheumatic AF, targeting an INR of 2.0–3.0, with weekly monitoring during initiation and monthly monitoring once stable. 1, 2
• Direct oral anticoagulants (DOACs) have not been systematically evaluated in rheumatic AF patients and current evidence supporting their use comes predominantly from nonvalvular AF populations. 3
• The FDA label for warfarin specifically recommends an INR of 2.0–3.0 for patients with AF and mitral stenosis. 2
• Monitor INR weekly during warfarin initiation, then monthly when the therapeutic range is stable. 1, 2

Pre-Cardioversion Anticoagulation

• For AF duration >48 hours or unknown duration, provide therapeutic anticoagulation (INR 2.0–3.0) for at least 3 weeks before cardioversion and continue for a minimum of 4 weeks afterward. 1
• Alternatively, perform transesophageal echocardiography to exclude left atrial thrombus; if negative, proceed with cardioversion after initiating heparin, but continue anticoagulation for at least 4 weeks post-procedure. 1
• Critical point: Continue lifelong anticoagulation based on the presence of rheumatic valvular disease, not on whether sinus rhythm is maintained. 1

---

Rhythm Control is Superior to Rate Control in Rheumatic AF

Unlike nonvalvular AF where rate control is the preferred initial strategy, rhythm control should be pursued in rheumatic AF patients because they are typically younger, more active, and demonstrate better outcomes with sinus rhythm maintenance. 4, 5, 6

Evidence Supporting Rhythm Control

• A landmark randomized trial in 144 rheumatic AF patients demonstrated that rhythm control resulted in zero deaths compared to 5 deaths in the rate control group (p=0.02) at 1 year. 4, 5
• Patients maintaining sinus rhythm showed significant improvement in exercise capacity (2.6±1.9 vs 0.6±2.5 minutes, p=0.001), functional class (p=0.002), and quality of life (p=0.01) compared to rate control. 5
• A recent 2024 study confirmed that 51.81% of rheumatic AF patients who achieved sinus rhythm had improved functional class, lower NT-proBNP, better 6-minute walk distance, and reduced heart failure hospitalizations. 6

Stepwise Rhythm Control Algorithm

Step 1: Initial Cardioversion Attempt

• Perform electrical (DC) cardioversion as the primary method to restore sinus rhythm. 4, 5, 6
• Ensure therapeutic anticoagulation for ≥3 weeks before elective cardioversion if AF duration >48 hours. 1
• Approximately 35% of patients maintain sinus rhythm after a single cardioversion without additional therapy. 6

Step 2: Pharmacological Rhythm Maintenance

• Amiodarone is the antiarrhythmic drug of choice for rheumatic AF patients. 4, 5
• Amiodarone achieved 69.1% sinus rhythm maintenance at 1 year versus 36.4% with placebo (p=0.008). 5
• Conversion rates with amiodarone were 88.4% versus 77.3% with placebo, though this difference was not statistically significant (p=0.49). 5
• Placebo-treated patients required significantly more electrical cardioversions (2.1 vs 1.4, p=0.011). 5

Step 3: Catheter Ablation (for Recurrent AF)

• Consider catheter ablation in patients with recurrent AF despite cardioversion and amiodarone therapy. 6
• Only 1 patient (1.2%) required AF ablation in the 2024 study, suggesting most patients respond to cardioversion ± amiodarone. 6

Step 4: Pace-and-Ablate Strategy (for Refractory Cases)

• For patients who fail rhythm control attempts, perform AV node ablation with permanent pacing. 6
• Hybrid approach: Implant an atrial lead in addition to ventricular pacing; 50% of patients with this strategy achieved and maintained sinus rhythm. 6
• Among 24 patients who underwent pace-and-ablate, none had heart failure hospitalizations, and those maintaining sinus rhythm had further clinical improvement. 6

Predictors of Successful Rhythm Control

• Duration of AF is the strongest predictor: Patients who achieved sinus rhythm had shorter AF duration (3.15±1.29 years) compared to those who remained in AF (6.69±5.23 years, p=0.041). 6
• Pursue rhythm control aggressively in patients with AF duration <3 years. 6

---

Rate Control Strategy (When Rhythm Control Fails or is Not Pursued)

Rate Control Medications by Left Ventricular Function

For Preserved LVEF (>40%):

• First-line agents are beta-blockers (metoprolol, atenolol, bisoprolol, carvedilol) or non-dihydropyridine calcium channel blockers (diltiazem, verapamil). 1, 7, 8
• Diltiazem dosing: 60–120 mg three times daily (or 120–360 mg extended-release). 7
• Verapamil dosing: 40–120 mg three times daily (or 120–480 mg extended-release). 7

For Reduced LVEF (≤40%) or Heart Failure:

• Use only beta-blockers and/or digoxin; avoid diltiazem and verapamil due to negative inotropic effects. 1, 7, 8
• Preferred beta-blockers: bisoprolol, carvedilol, long-acting metoprolol. 7
• Digoxin dosing: 0.0625–0.25 mg daily. 7

Rate Control Targets

• Lenient rate control (resting heart rate <110 bpm) is acceptable as the initial target for most patients. 1, 7
• Pursue strict rate control (resting heart rate <80 bpm) only if symptoms persist despite lenient control. 1, 7

Combination Therapy

• If monotherapy fails, combine digoxin with a beta-blocker or calcium channel blocker for better control at rest and during exercise. 1
• Monitor closely for bradycardia when using combination therapy. 1, 8

Critical Pitfall

• Never use digoxin as monotherapy in active or young rheumatic AF patients, as it only controls rate at rest and is ineffective during exercise or sympathetic surges. 1, 9

---

Special Clinical Scenarios

Hemodynamic Instability

• Perform immediate synchronized electrical cardioversion without awaiting anticoagulation in patients with hypotension, acute heart failure, ongoing chest pain, or pulmonary edema. 1, 7, 9

Chronic Obstructive Pulmonary Disease

• Prefer non-dihydropyridine calcium channel blockers (diltiazem or verapamil) and avoid beta-blockers. 1, 7

Wolff-Parkinson-White Syndrome with Pre-excited AF

• Avoid all AV nodal blocking agents (adenosine, beta-blockers, calcium channel blockers, digoxin, amiodarone) as they may accelerate ventricular rate and precipitate ventricular fibrillation. 1, 7
• If hemodynamically unstable, perform immediate electrical cardioversion. 1, 7
• If stable, administer IV procainamide or ibutilide. 1, 7

---

Common Pitfalls to Avoid

• Never discontinue anticoagulation solely because sinus rhythm has been achieved; rheumatic valvular disease mandates lifelong anticoagulation regardless of rhythm status. 1, 3
• Do not rely on CHA₂DS₂-VASc score for anticoagulation decisions in rheumatic AF; the presence of rheumatic mitral stenosis alone is a Class I indication for anticoagulation. 1, 2
• Do not assume that rate control is adequate without assessing exercise tolerance; many young rheumatic AF patients remain symptomatic despite acceptable resting heart rates. 5, 3
• Do not delay rhythm control attempts in young patients with recent-onset AF (<3 years duration), as success rates decline significantly with longer AF duration. 6